Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - OTC Markets Other stock markets 12:54:51 2024-05-24 EDT			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

25-05-26	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
24-07-22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT

Market Cap	2.62M 2.26M 2.08M 1.95M 3.66M 249M 3.71M 24.61M 9.59M 121M 9.83M 9.62M 419M	P/E Ratio 2022	-1.04x	P/E Ratio 2023	-0.72x
Enterprise Value	39.01M 33.69M 31.05M 29.06M 54.46M 3.71B 55.3M 367M 143M 1.8B 146M 143M 6.25B	EV / Sales 2022	-	EV / Sales 2023	51,081,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

25-05-26	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
24-07-22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
24-06-18	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
24-06-18	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
24-06-18	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
24-06-17	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24-05-23	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-09	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
24-04-04	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
24-03-28	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
24-03-28	Top Premarket Decliners	MT
24-03-27	Top Midday Decliners	MT
24-03-27	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

24-01-29	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
23-11-15	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
23-11-15	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
23-05-19	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
23-05-16	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

Gamida Cell Ltd. Stock

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation: Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

24-03-27	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
24-03-27	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
24-03-22	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
24-02-23	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
24-01-29	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	2021-05-31
Rory Nealon COO	Chief Operating Officer	58	2024-05-23

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	2019-03-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-01-30	Ronit Simantov	Free	Chief Technology Officer	480,319	0.3621%
24-01-30	Kenneth Moch	Free	Director	200,000	0.1508%
24-01-30	Stephen Wills	Free	Director	200,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-99.18%	2.62M
ARGENX SE	+1.03%	+2.30%	+55.91%	+115.16%	56.42B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+46.05%	+47.37%	44.54B
BIONTECH SE	+1.12%	+2.79%	-15.04%	-18.40%	22.9B
INSMED INCORPORATED	+1.17%	+3.85%	-0.89%	+407.26%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+11.00%	-29.60%	16.4B
GENMAB A/S	+0.15%	+2.24%	+9.32%	-39.25%	15.4B
EXELIXIS, INC.	-0.69%	+0.82%	+27.75%	+182.91%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+19.65%	-	12.36B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+95.75%	+206.59%	11.15B
Average	+1.86%	+2.25%	+24.95%	+85.87%	21.37B
Weighted average by Cap.	+1.72%	+2.37%	+32.04%	+101.70%

	2022	2023
Net sales	-	1.78 1.54 1.42 1.33 2.49 169.57 2.53 16.77 6.54 82.54 6.7 6.55 285.78
Net income	-79.38M -68.56M -63.17M -59.13M -111M -7.54B -113M -746M -291M -3.67B -298M -292M -12.72B	-63M -54.41M -50.14M -46.93M -87.95M -5.99B -89.32M -592M -231M -2.91B -236M -231M -10.09B
Net Debt	39.31M 33.95M 31.29M 29.28M 54.88M 3.74B 55.73M 369M 144M 1.82B 148M 144M 6.3B	36.39M 31.43M 28.96M 27.11M 50.81M 3.46B 51.59M 342M 133M 1.68B 137M 134M 5.83B

3 years	0.01	1.98
5 years	0.01	6.84
10 years	0.01	15.41